Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notification of half year results

4th Feb 2020 09:00

RNS Number : 8047B
Clinigen Group plc
04 February 2020
 

4 February 2020

 

Notification of half year results date

 

Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its half year results for the six months ended 31 December 2019 on Tuesday 25 February 2020.

 

A group analyst briefing will be held at 9:30am on Tuesday 25 February 2020 at Instinctif Partners' offices at65 Gresham Street, London EC2V 7NQ.

 

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email [email protected] to register.

 

-Ends-

 

 

For further information, please contact:

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Nick Keher, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations

Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Freddie Barnfield

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Phil Marriage

Email: [email protected]

 

Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information, please visit www.clinigengroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORKKNBBABKDQBK

Related Shares:

CLIN.L
FTSE 100 Latest
Value8,440.69
Change25.44